2 news items
Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
THTX
23 May 24
a clinical benefit rate (complete response + partial response + stable disease), as confirmed via Response Evaluation Criteria in Solid Tumors (RECIST
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technologyâ„¢ Oncology Platform
THTX
8 Apr 24
, camptothecin-peptide conjugates and sudocetaxel zendusortide, their use and the potential benefits to be derived from their use. Although the Forward-Looking
- Prev
- 1
- Next